S-ketamine in patient-controlled analgesia with oxycodone improves analgesia in a dose-dependent manner after major lumbar fusion surgery: a randomized, double-blind, placebo-controlled clinical trial

Elina C.V. Brinck[1,2,#a ¶], Taru Virtanen[3,¶, #b], Sanna Mäkelä[4], Venla Soini[5], Ville-Veikko Hynninen[4], Jukka Mulo[4], Urmas Savolainen[4], Juho Rantakokko[5], Kreu Maisniemi[1], Antti Liukas[3], Klaus T. Olkkola[2], Vesa Kontinen[6], Pekka Tarkkila[1], Marko Peltoniemi[3], Teijo I. Saari[3,4, #b]

[1]Department of Anaesthesiology, Töölö Hospital, Division of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

[2]Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

[3]Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland

[4]Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku University Hospital

[5]Division of the musculoskeletal system at Turku University Hospital, Turku University Hospital, Department of Orthopaedics, University of Turku, Turku, Finland.

[6]Department of Anaesthesiology, Jorvi Hospital, Division of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

[#a] Current address: Department of Anesthesiology, Töölö Hospital, HUS Helsinki University Hospital, Helsinki, Finland

[#b] Current address: Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland

* Corresponding author

Email: teisaa@utu.fi (TIS)

Abstract

BACKGROUND: Spinal fusion surgery causes severe pain. Strong opioids, commonly used as postoperative analgesics, may have unwanted side effects. S-ketamine may be an effective analgesic adjuvant in opioid patient-controlled analgesia (PCA). However, the optimal adjunct S-ketamine dose to reduce postoperative opioid consumption is still unknown.

METHODS: We randomized 107 patients at two tertiary hospitals in a double-blinded, placebo-controlled clinical trial of adults undergoing major lumbar spinal fusion surgery. Patients were randomly allocated to four groups in order to compare the effects of three different doses of adjunct S-ketamine (0.25, 0.5, and 0.75 mg ml-1) or placebo on postoperative analgesia in oxycodone PCA. Study drugs were administered for 24 hours postoperative after which oxycodone-PCA was continued for further 48 hours. Our primary outcome was cumulative oxycodone consumption at 24 hours after surgery.

RESULTS: Of the 100 patients analyzed, patients receiving 0.75 mg ml^{-1} S-ketamine in oxycodone PCA needed 25% less oxycodone at 24 h postoperatively (61.2 mg) compared with patients receiving 0.5 mg ml^{-1} (74.7 mg) or 0.25 mg ml^{-1} (74.1 mg) S-ketamine in oxycodone or oxycodone alone (81.9 mg) (mean difference: -20.6 mg; 95% confidence interval [CI]: -41 to -0.20; $P = 0.048$). A significant beneficial effect in mean change of pain intensity at rest was seen in the group receiving 0.75 mg ml^{-1} S-ketamine in oxycodone PCA compared with patients receiving lower ketamine doses or oxycodone alone (standardized effect size: 0.17, 95% CI: 0.013–0.32, $P = 0.033$). The occurrence of adverse events was similar among the groups.

CONCLUSIONS: Oxycodone PCA containing S-ketamine as an adjunct at a ratio of 1: 0.75 decreased cumulative oxycodone consumption at 24 h after major lumbar spinal fusion surgery without additional adverse effects.

53 **Introduction**

54 Severe postoperative pain is common after major spinal fusion surgery.[1] Inadequate pain
55 management is associated with increased postoperative complications, delayed ambulation, and
56 chronic postoperative pain.[2] This may lead to unplanned readmission after surgery, decreased
57 patient satisfaction, and increased health-care costs. Opioids have been the cornerstone of
58 postoperative analgesia after major surgery, but the increasing awareness of the problems
59 associated with their use, such as opioid-associated adverse effects, opioid-induced hyperalgesia,
60 and the risk of addiction, combined with the current opioid crisis has encouraged the search for
61 alternative analgesic strategies.

62 Multimodal analgesia targets different pain signaling pathways by combining two or more
63 analgesic modalities, aiming at additive or even synergistic analgesic effect.[3] Multimodal
64 analgesia has proven feasible after major spinal fusion surgery in an effort to optimize pain relief
65 while minimizing opioid-related adverse effects.[4,5]

66 Patient-controlled analgesia (PCA) use is associated with lower pain intensity and greater patient
67 satisfaction compared with conventional (oral, subcutaneous, or intramuscular) administration
68 routes.[6] PCA may enhance patient autonomy because the analgesic drug is readily available.
69 Morphine is the most frequently used opioid in PCA, while oxycodone use is associated with
70 higher patient satisfaction scores.[6,7]

71 Low-dose (<1 mg kg^{-1}) ketamine inhibits N-methyl-D-aspartate receptors in nociceptive neurons
72 and activates descending inhibitory pain pathways, resulting in attenuated wind up and central
73 sensitization.[8-11] The effect of perioperative intravenous ketamine as an adjunct analgesic has
74 been documented in several clinical trials and meta-analyses.[12] A recent review article concluded

that combining ketamine with an opioid in IV-PCA during the postoperative period has a beneficial effect on analgesia and opioid consumption.[13] In orthopedic surgery, earlier trials found negative or unclear results with opioid-ketamine PCA.[14-16] However, studies' vast heterogeneity and small sample sizes have failed to establish a possible a possible dose-responsiveness. Thus, the optimal ketamine to opioid ratio in intravenous PCA is yet to be elucidated.

We hypothesized that adjunct S-ketamine with oxycodone in an intravenous PCA is superior to oxycodone, with reduced opioid-associated adverse events in the immediate postoperative period after major spinal surgery. This randomized, double-blind, placebo-controlled study compared three different doses of S-ketamine with placebo added as an adjuvant to oxycodone IV-PCA administered for 24 hours after lumbar spinal fusion in adult patients. After the study phase, IV oxycodone-PCA without ketamine was continued for further 48 hours. The primary outcome was cumulative oxycodone consumption at 24 h after surgery. The secondary endpoints included postoperative pain intensity, oxycodone consumption, and occurrence of adverse events up to 72 h after surgery.

91 **Methods**

92 Ethics and registration

93 This study (DoseRespKeta) was approved by the institutional review board of the Hospital
94 District of Southwest Finland (number: *103/1800/2016*) and the Finnish Medicines Agency
95 (FIMEA, KL 135/2016). The trial was registered before patient enrollment at clinicaltrials.gov
96 (NCT02994173; Principal investigator: TIS; Date of registration: September 11, 2017) and in the
97 EudraCT database (*2016-002887-14*; Principal investigator: TIS; Date of registration: October
98 12, 2016). No changes to methods were made after trial commencement. The detailed study
99 protocol is available upon request from the authors. Written informed consent was obtained from
100 the participants before inclusion to the study. This manuscript complies with the Consolidated
101 Standards of Reporting Trials guidelines.

102 Patient population

103 This two-center study was carried out at the T-hospital and TYKS ORTO units at Turku
104 University Hospital in Turku, Southwest Finland and the HUS Helsinki University Hospital's
105 Töölö Unit in Helsinki, Finland. One hundred and seven adult patients scheduled for elective
106 posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation under
107 general anesthesia were recruited between 6 February 2017 and 31 October 2019 (Fig 1).



Figure 1. DoseRespKeta trial structure and CONSORT 2009 flow diagram. CONSORT indicates Consolidated Standards of Reporting Trials.

111

112 Patients with previous history of intolerance to a study drug, concomitant drug therapy with
113 strong opioids or strong cytochrome P450 3A4 or 2B6 inductor or inhibitors 2 weeks prior to
114 study, younger than 20 years and older than 80 years, BMI >35, sleep apnea or any other sleep
115 disorder, existing significant liver or kidney disease, history of alcoholism, drug abuse, and
116 psychological or other emotional problems likely to invalidate informed consent were excluded.
117 Patients were pre-screened by a preoperative care nurse. Potentially eligible subjects were
118 directed to investigators for further screening and information. ECVB and MP enrolled all
119 participants.

120

121 Study design, randomization, and blinding

122 A randomized, double-blind, controlled dose-response study design was used (Fig 1). The
123 allocation ratio was 1:1:1:1. Subjects were randomly assigned to one of four dosing groups (G)
124 for intravenous PCA:

125 - G1, oxycodone 1 mg ml^{-1} alone
126 - G2, oxycodone 1 mg ml^{-1} + S-ketamine 0.25 mg ml^{-1} (ratio 1:0.25)
127 - G3, oxycodone 1 mg ml^{-1} + S-ketamine 0.5 mg ml^{-1} (ratio 1:0.5),
128 - G4, oxycodone 1 mg ml^{-1} + S-ketamine 0.75 mg ml^{-1} (ratio 1:0.75).

129 An independent statistician created a computer-generated randomization list. The list was sent to
130 the local hospital pharmacy, which took care of assignment. Coded PCA reservoirs with no other
131 markings were delivered to the operation room by the pharmacy on the day of surgery to ensure
132 double blinding. Patients, researchers, and clinical staff were blinded to group allocation.

133 Conduct of the study and anesthesia

134 After providing written informed consent, patients learned to use the PCA system (CADD®-
135 Solis VIP and CADD-Legacy® PCA Pump Model 6300, Smiths Medical, Minneapolis, MN,
136 USA) and numerical rating scale (NRS; 0 denotes no pain, and 10 indicates the worst imaginable
137 pain). Preoperatively, all patients received 1000 mg of paracetamol orally. Routine anesthetic
138 monitoring included pulse oximetry, electrocardiography, invasive blood pressure via radial
139 artery cannulation, and body temperature measurement. General anesthesia was induced and
140 maintained with propofol (Propofol-Lipuro 20 mg ml^{-1}; B. Braun Melsungen AG, Melsungen,
141 Germany) and remifentanil (Remifentanil B. Braun 1 mg ml^{-1}; B. Braun Melsungen AG,
142 Melsungen, Germany) target-controlled infusions. Schnider- and Minto-effect-site models were
143 used for propofol and remifentanil, respectively.[17,18] No opioids other than remifentanil were
144 used before or during anesthesia. Rocuronium bromide (Esmeron 10 mg ml^{-1}; Merck Sharp &
145 Dohme B.V., BN Haarlem, The Netherlands) 0.4–0.6 mg kg^{-1} facilitated endotracheal intubation.
146 The depth of anesthesia (bispectral index BIS or entropy index) was targeted from 45 to 55 with
147 entropy (GE B850 Monitor Entropy Module, GE, Helsinki, Finland) or BIS monitor (The Philips
148 BIS module, Philips Medical Systems, Eindhoven, The Netherlands). Mean arterial pressure
149 (MAP) was maintained at 65–75 mmHg. Intravenous bolus doses of ephedrine and/or
150 noradrenaline infusion were administered if necessary. Local anesthetic was injected to the skin
151 incision area before incision (lidocaine 5 mg kg^{-1} c. adrenaline 5 µg kg^{-1}; Orion Pharma, Espoo,
152 Finland) and after wound closure (levobupivacaine 2.5 mg kg^{-1}; Chirocaine 2.5 mg ml^{-1}, AbbVie
153 S.r.l., Campoverde di Aprilia, Italy) as per hospital routines.

154 At the end of surgery, the PCA pump was attached to the intravenous line and activated. The first
155 dose of PCA solution was given just after the cessation of propofol and remifentanil infusions,

156 before patients woke up from anesthesia. As soon as the patient awoke, they were encouraged to
157 use PCA to treat postoperative pain if necessary. The starting dose of oxycodone (Oxycodone
158 Orion 10 mg ml^{-1}; Orion Pharma, Espoo, Finland) in the PCA solution was 2 mg with a lockout
159 interval of 5 min. When NRS was 4 or lower, the PCA oxycodone dose was decreased to 1 mg
160 (G1–G4). The study PCA dosing continued for 24 h from the end of surgery. Thereafter, the
161 PCA cassette was changed to only an oxycodone-containing solution (G1). The total duration of
162 PCA treatment was three days. Postoperative nausea and vomiting (PONV) were treated with
163 intravenous ondansetron and dehydrobenzperidol if necessary. Potential excessive unpleasant
164 psychotomimetic effects from S-ketamine (Ketanest-S 5 mg ml^{-1}; Pfizer Manufacturing Belgium
165 NV, Puurs, Belgium) were treated with 1 mg intravenous bolus of lorazepam.

166 Measurements and data handling

167 Heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, NRS (0–10) for pain
168 intensity at rest and upon movement, level of sedation with the Richmond Agitation-Sedation
169 scale (RASS), nausea, vomiting, pruritus, unpleasant dreams or any other adverse effect or
170 sensation thought to be caused by PCA, cumulative PCA pressings, or the doses given were
171 registered immediately after arrival in the recovery room and at the following time points: five,
172 30, 60 , 120, and 240 minutes and eight, 24, 48, and 72 hours later. Patients evaluated their pain
173 relief satisfaction (yes/no) at the end of postoperative days 1–3.

174 All clinical patient data were collected on individual case report forms. All data were
175 subsequently transferred to electronic format for exploratory data analysis.

176 Primary and secondary outcomes

177 The primary endpoint was cumulative oxycodone consumption at 24 h after surgery, the end of
178 period when three different ratios of S-ketamine were added to oxycodone PCA solution.

179 Secondary outcomes were NRS and RASS ratings, oxycodone consumption, PONV, pruritus,
180 and unpleasant dreams or other adverse effects.

181 Sample size calculation

182 Based on a previous study,[19] we calculated that 25 patients per group were necessary to
183 demonstrate a clinically significant 25% reduction in oxycodone consumption with a level of
184 significance of $P = 0.05$ and power of 80%.

185 Statistical analyses

186 The authors approved the statistical analysis plan before the analyses began. Explorative data
187 analysis was conducted before statistical inference by plotting and tabulating the data. Normality
188 assumptions were tested before analysis, using probit plots and the Shapiro–Wilk W-test.
189 Levene's test was used to evaluate homogeneity of variances.

190 The primary outcome measure, cumulative opioid consumption during the first 24 h is presented
191 as both median and interquartile range (IQR; Q1–Q3) and mean (SD). Cumulative opioid
192 consumption at 24, 48, and 72 h was analyzed by using a linear mixed model for repeated
193 measurements. The model included the following factors: PCA dosing groups G1–G4, age (as a
194 continuous covariate), age, gender, prior use of opioids (yes/no), prior use of gabapentinoids
195 (yes/no), cumulative amount of dose requests during PCA, and postoperative time (24, 48, and
196 72 h). In addition, the interaction with time and opioid consumption and prior use of weak
197 opioids was examined. Non-significant terms were excluded from the final model. An

198 unstructured covariance structure was used. Square-root transformation was used to fulfill
199 assumptions of the model. Studentized residuals were used to check assumptions.

200 To study pain burden, we analyzed if the mean change in NRS over time differed between the
201 groups during the first 24 hours postoperatively. A hierarchical linear mixed model was used
202 including time as a within-factor (with five time points), PCA dosing group as a between-factor,
203 and their interaction. The time factor was handled as categorical to estimate all possible shapes
204 of mean changes over time. NRS values were standardized before analysis by centering and
205 scaling to have a mean of zero and a SD of one. Effect sizes were computed as the eta squared
206 based on the H-statistic.[20] We also studied in a separate model, whether age, sex, weight, chronic
207 pain, and prior use of weak opioids or gabapentinoids affected the results. Differences in NRS
208 and sedation (measured with RASS) between the groups were evaluated at the end of post-
209 anesthesia care unit (PACU) treatment (t = 480 min) and at 24 h with a Kruskal–Wallis test.

210 Differences in postoperative nausea and vomiting, pruritus, and unpleasant dreams (yes/no)
211 among groups at 24, 48, and 72 h postoperatively were evaluated with ordinal logistic regression.
212 The effect of age, sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids on
213 the results were tested as covariate effects. To analyze the effect of adjuvant ketamine treatment
214 on these parameters, we included changes in parameters to the model during the previous 24 h.

215 Descriptive statistics are shown as means and SD when variables are normally distributed and
216 otherwise as medians and IRQs. Categorical variables are summarized as counts and
217 percentages. The statistical significance level was set to $P < 0.05$. RStudio (version 1.0.153)[21]
218 with R (version 3.6.0)[22] and ggplot2 (version 2.2.1) were used for statistical analyses and
219 graphical presentations.

Results

A total of 231 patients were assessed for eligibility. 107 patients were recruited in the study (Fig 1B) between February 2017 and October 2019. Two patients withdrew their consent before randomization and were excluded. Two patients were further excluded due to logistical reasons before surgery. In one case, the operation plan was changed after randomization and this patient was also excluded from the study. Two more patients withdrew consent during the first 24 h after the start of intervention and were excluded from the final analysis. Thus, 25 patients in each of the four groups were included in the analysis. Patient median age was 60 (28–78) years and 77% were women. No significant differences in baselines characteristics were present among the groups (Table 1).

230 **Table 1.** Perioperative Data and Characteristics of Patients Who Were Included in the Analysis.

	All	G1	G2	Standardized Differences Between G1 and G2	G3	Standardized Differences Between G1 and G3	G4	Standardized Differences Between G1 and G4
n	100	25	25		25		25	
Age, yr (median, range)	60 (28-78)[2]	56 (34-78)	62 (28-76)	0.214	60 (40-75)	0.433	62 (30-76)	0.329
Female/male, n (%)	45/55	11/14 (44%)[1]	11/14 (44%)	<0.001	12/13 (48%)	<0.001	11/14 (44%)	0.08
Body weight (kg)	77.7 (15.6)	77.7 (15.6)	74.9 (15.9)	0.215	79.0 (14.1)	0.278	77.0 (11.2)	0.156
BMI (kg/m^{-2})	26.9 (4.3)	26.6 (4.6)	27.3 (4.3)	0.003	26.9 (3.5)	0.152	26.8 (4.9)	0.063
Smoking (yes/no), n (%)	9/91	1/24 (4%)	3/22 (12%)	0.169	3/22 (12%)	0.298	2/23 (7.7%)	0.298
Previous chronic pain (yes/no), n (%)	15/85	22/3 (88%)[1]	19/6 (76%)	0.115	22/3 (88%)	0.316	22/3 (88%)	<0.001
Median [IRQ] preoperative pain intensity (NRS)	6 [4, 8]	6 [5, 7]	5 [5, 7]	0.1	7 [5. 8]	0.42	7 [5. 8]	0.023
Preoperative opioid (yes/no), n (%)	5/94	2/23 (8.0%)[1]	2/23 (8.0%)	0.169	0/25 (0%)	<0.001	1/24 (3.8%)	0.417
Preoperative gabapentinod (yes/no), n (%)	18/82	3/22 (12%)[1]	3/22 (12%)	0.22	7/18 (28%)	<0.001	5/20 (19%)	0.408
Diabetes (yes/no), n (%)	8/92	1/24 (4.0%)[1]	3/22 (12%)	0.169	1/25 (4.0%)	0.298	3/22 (11%)	<0.001
ASA physical status, n (%)				0.408		0.182		0.331
1	24	7 (28.0)	6 (24.0)		6 (24.0)		5 (20.0)	
2	66	17 (68.0)	15 (60.0)		17 (68.0)		17 (68.0)	
3	10	1 (4.0)	4 (16.0)		2 (8.0)		3 (12.0)	

Duration of surgery (min)	306 (94)	325 (89)	292 (64)	0.424	303 (125)	0.202	305 (89)	0.226
Propofol during surgery (mg□kg^{-1})	37 (12)	39 (11)	36 (8)	0.259	35 (17)	0.26	36 (10)	0.248
Remifentanil during surgery (µg□kg^{-1}□min^{-1})	0.12 (0.05)	0.13 (0.06)	0.12 (0.04)	0.27	0.11 (0.04)	0.429	0.11 (0.04)	0.383

Data are mean (standard deviation) or [range) unless otherwise stated. Standardized difference is the difference in the mean of a variable between 2 groups divided by an estimate of the standard deviation of that variable.[21]

G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).; n, number of non-missing value; BMI, body-mass index; IQR, interquartile range; NRS, numerical rating scale; ASA, American Society of Anesthesiologists.

[1]Percentage of females or yes-answers

239 Opioid consumption

240 Cumulative oxycodone consumption was highest in group G1 and lowest in G4 (Fig 2, Table 2).
241 The median total oxycodone consumption during the first 24 h after surgery was 81.9 mg (IQR:
242 63.2–101), 74.1 mg (IQR: 62.1–86.1), 74.7 mg (IQR: 62.2–87.1), and 61.3 mg (IQR: 48.7–73.8)
243 in groups G1–G4, respectively. Postoperative cumulative oxycodone consumption was
244 significantly reduced in the group with the highest ketamine concentration (G4) compared with
245 the control group (G1): the mean difference was -21 mg (95% CI: -41 to -0.2, P = 0.048), -26
246 mg (95% CI: -55 to -6.2, P = 0.044) and -41 mg (95% CI: -68 to -14, P = 0.003) at 24, 48, and
247 72 h after surgery, respectively (Fig 2). There was no significant difference in time to dose
248 reduction from 2 mg to 1 mg PCA-bolus among groups (median [IQR]: 125 min [78–203], 127
249 min [82–174], 112 min [69–185] and 145 min [79–211] in groups G1–G4, respectively, P =
250 0.838).



251

252 **Figure 2.** Postoperative cumulative oxycodone consumption during the first 24 h in four patient-
253 controlled analgesia (PCA) treatment groups (G1¬–G4). PCA, patient-controlled analgesia. Box
254 plots show the median and 25–75th percentiles, and the whiskers indicate the minimum and
255 maximum. Blue diamonds show the mean oxycodone consumption in each plot.

256 **Table 2**. Oxycodone consumption during the study after the beginning of PACU care

Time after PACU start	All (n=100)	G1 (n=25)	G2 (n=25)	G3 (n=25)	G4 (n=25)
60 min					
Mean (SD)	10.9 (4.2)	11.9 (3.4)	10.3 (3.9)	11.3 (4.2)	10.4 (5.1)
Median [IRQ]	10.0 [8.00, 14.0]	12.0 [8.0, 16.0]	10.0 [7.40, 14.0]	10.0 [8.0, 14.0]	12.0 [6.00, 14.0]
120 min					
Mean (SD)	19.2 (7.2)	21.2 (6.6)	18.2 (5.6)	20.0 (8.5)	17.3 (7.5)
Median [IRQ]	18.0 [14.0, 24.0]	21.0 [16.0, 25.0]	18.0 [16.0, 22.0]	18.0 [13.3, 24.0]	15.0 [12.0, 24.0]
240 min					
Mean (SD)	28.2 (12.5)	31.0 (13.0)	26.5 (9.3)	28.6 (14.8)	26.7 (12.6)
Median [IRQ]	26.8 [20.0, 35.0]	28.0 [25.0, 35.0]	26.6 [23.0, 34.0]	24.0 [18.0, 36.0]	26.0 [18.0, 34.0]
480 min					
Mean (SD)	35.5 [26.8, 46.3)	37.0 [31.0, 44.0)	34.0 [29.0, 49.0)	33.0 [26.0, 49.0)	36.0 [23.0, 45.0)
Median [IRQ]	37.6 (16.7)	39.6 (16.9)	36.4 (13.1)	39.1 (18.3)	35.5 (18.5)
24 h					
Mean (SD)	65.0 [46.8, 93.7)	65.0 [55.0, 104)	71.0 [48.0, 93.6)	71.0 [51.3, 93.0)	51.0 [42.0, 78.0)
Median [IRQ]	72.9 (36.5)	81.9 (47.6)	74.1 (30.7)	74.7 (31.8)	61.3 (32.3)
48 h					
Mean (SD)	117 (74.0)	137 (96)	118 (67.5)	121 (63.6)	90.8 (57.3)
Median [IRQ]	99.0 (65.2, 136)	118.0 (73.2, 147)	94.3 (73.2, 135)	112.0 (72.0, 130)	73.5 (52.0, 120)
72 h					

Mean (SD)	145 (95.6)	170 (123)	156 (97.7)	146 (67.0)	109 (73.3)
Median [IRQ]	127 [77.5, 170]	150 [88.2, 170]	128 [90.0, 189]	129 [97.0, 178]	89.0 [56.8, 147]

257

258 PACU, postoperative care unit, G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous
259 oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml
260 (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

261 Acute pain measurements during postoperative care

262 Postoperative mean change in NRS measured at rest over the first 24 h differed significantly
263 between groups G4 and G1 (standardized effect size: 0.17, 95% CI: 0.013–0.32, $P = 0.033$), but
264 not between group G3 and G1 (standardized effect size: -0.097, 95% CI: -0.25–0.059, $P = 0.223$)
265 or G2 and G1 (standardized effect size -0.052, 95% CI: -0.21–0.10, $P = 0.51$) (Fig 3A). Age,
266 sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids had no effect on the
267 results.



268

269 **Figure 3.** A) Patient-reported numerical rating scale (NRS) values at rest during the first 24 h in
270 four patient-controlled analgesia (PCA) treatment groups G1-G4. Box plots show the median
271 and 25–75th percentiles, and the whiskers indicate the minimum and maximum. (B) Risk ratios
272 (95% CI) for reporting NRS value 4 or higher. PACU, postoperative care unit; CI, confidence
273 interval.

274

275 To evaluate the effect of patient satisfaction, we analyzed the risk of having NRS >3 at rest at
276 different timepoints during PACU treatment. For this purpose, NRS values were dichotomized
277 depending on the pain level that patients experienced (NRS >3 or NRS ≤3). Although patient
278 satisfaction, measured by patient-reported NRS was smaller in groups G2–G4 than group G1 at
279 the end of PACU treatment, the finding was not statistically significant (Fig 3B).

280 Postoperative sedation

281 At arrival to PACU, median (IQR) RASS was -1 (-2–0), and all patients were cooperative. RASS
282 increased to 0 (-1 to 0) within the following 30 minutes. After 60 minutes, all patients were fully
283 awake (median [IQR] RASS: 0 [0, 0]), and they remained fully awake until the end of the study.
284 No significant differences in RASS scores were present between the groups during the 72-hour
285 follow-up (Table 3).

286 **----- Table 3 here -----**

287 **Table 3.** Opioid related adverse events during the study.

288

Adverse effect		All	G1	G2	G3	G4
Sedation (RASS-scale)						
0 min		-1 [-2, 0][1]	-1 [-2, 0]	-1 [-3, 0]	-1 [-1,0]	-1 [-2, 0]
5 min		-1 [-2, 0]	-1 [-2, 0]	0 [-1, 0]	0 [0,-1]	-1 [-1, 0]
30 min		0 [0, 1]	0 [0,-1]	0 [-1, 0]	0 [-1, 1]	0 [-1, 0]
60 min		0 [0, 0]	0 [0,-1]	0 [0, 0]	0 [0, 0]	0 [0, 0]
2 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
4 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
8 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
24 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
PONV		n=100	n=23	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	2 (8)	3 (12)	6 (24)	5 (22)
	No (%)	82 (82)	23 (92)	22 (88)	19 (76)	18 (78)

48 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
	No (%)	90 (90)	21 (84)	24 (96)	20 (80)	20 (87)
72 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
	No (%)	90 (90)	21 (84)	24 (96)	20 (80)	20 (87)
Pruritus		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	4 (16)	7 (28)	4 (16)	1 (4)
	No (%)	84 (84)	21 (84)	18 (72)	21 (84)	24 (96)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
	No (%)	90 (90)	21 (84)	21 (84)	24 (96)	24
72 hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)
	No (%)	93 (93)	23(92)	24 (96)	23 (92)	23 (92)
Unpleasant dreams		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	9 (9)	2 (8)	2 (8)	2 (8)	3 (12)
	No (%)	91 (91)	23 (92)	23 (92)	23 (92)	22 (88)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
	No (%)	90 (90)	21 (84)	21 (84)	24 (96)	24 (96)
72hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)
	No (%)	93 (93)	23(92)	24 (96)	23 (92)	23 (92)

[1] RASS-scale given as median [interquartile range]

RASS, Richmond Agitation-Sedation Scale; PONV, postoperative nausea and vomiting; G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

Opioid-related adverse effects

Opioid-related adverse events during the study are summarized in Table 3. Nausea and vomiting were the most frequent adverse events. At 24 h after PCA start, 16% of patients (n = 16) reported nausea. Increasing ketamine dose seemed to increase the incidence of PONV, but the changes

301 were not statistically significant. Similarly, no differences were seen at the end of 48- and 72-h
302 follow-up. We analyzed these adverse effects further with logistic regression. Our results
303 indicate that preoperative weak opioid use increased the incidence of PONV significantly (odds
304 ratio: 9.23, 95% CI: 1.4–75). Adjuvant ketamine in PCA had no effect (odds ratio: 3.9, 95% CI:
305 0.68–4.7) on PONV, and after changing to normal PCA with only oxycodone at 24 h, the
306 incidence of PONV did not change (odds ratio: 0.53, 95% CI: 0.62–4.7).

307 At 24 h after PCA start, 16% of patients (n = 16) reported pruritus (Table 3). The PCA treatment
308 groups did not show statistically significant differences at any of the three time points (24, 48, or
309 72 h after the start of PCA). Similarly, the incidence of pruritus did not change after changing to
310 normal PCA with oxycodone only.

311 Nine patients (9%) reported nightmares or unpleasant dreams (Table 3). The groups showed no
312 difference in this regard, and the incidence did not change after changing to normal PCA with
313 oxycodone only. Age, sex, weight, chronic pain, and prior use of gabapentinoids had no effect on
314 the results.

315 Other adverse effects

316 There were no severe adverse effects. None of the patients developed respiratory insufficiency
317 requiring invasive or non-invasive ventilation during the 72-h study period. No rescue
318 medications were required during the study.

319 **Discussion**

320 This randomized, double-blind, placebo-controlled study evaluated the effect of adding
321 incremental doses of S-ketamine to oxycodone PCA in patients who underwent major lumbar
322 spinal fusion surgery. Our results demonstrate that patients who received oxycodone:S-ketamine
323 ratio 1:0.75 (a bolus containing oxycodone 1 mg + S-ketamine 0.75mg per ml) for postoperative
324 analgesia consumed significantly less oxycodone at 24 h postoperatively compared with
325 participants who received lower S-ketamine doses or oxycodone alone.

326 A significant beneficial effect in mean change in pain intensity at rest was seen in the group
327 receiving 0.75 mg ml^{-1} S-ketamine in oxycodone PCA compared with patients receiving lower
328 doses of ketamine or oxycodone alone. Cumulative oxycodone dose or adjunct S-ketamine did
329 not significantly influence postoperative nausea and vomiting. Occurrence of pruritus,
330 nightmares, or unpleasant dreams did not differ significantly among study groups.

331 Major spinal surgery is increasing in frequency and complexity. It is associated with severe
332 postoperative pain,[1] which is not easily amenable to regional anesthesia and requires a
333 multimodal approach. This is a crowded field of clinical research, with many previous studies
334 evaluating various single doses of ketamine with different opioids in many types of surgery. Yet,
335 there is little previous data that assesses the effect of adjunct ketamine to an IV opioid-PCA
336 exclusively after lumbar spinal fusion surgery in an opioid-naïve patient population. A recent
337 review and meta-analysis evaluated the effect of perioperative ketamine for analgesia in spine
338 surgery.[24] However, in most of the included trials, ketamine was administered intraoperatively
339 followed by postoperative IV-PCA or ketamine was given both as a pre-incisional bolus and as a
340 postoperative IV-PCA with a background infusion and a bolus on-demand.[25,26] This may confuse
341 evaluation of the analgesic effect of IV-PCA administration of ketamine with an opioid.

342 Additionally, the meta-analysis included patients undergoing lumbar microdiscectomy with
343 postoperative opioid IV-PCA.[27] It could be anticipated that pain after lumbar microdiscectomy is
344 less severe than after major lumbar spinal fusion surgery, and thus postoperative conditions are
345 not comparable. Furthermore, one previous study was an open-label trial[28] and another had only
346 female patients,[29] making it difficult to generalize results.

347 Previous studies have shown an opioid-sparing effect of intravenous low-dose ketamine after
348 spine surgery in opioid-dependent patients.[30, 31] Additionally, Loftus (2010) and Nielsen (2017)
349 showed that the benefit of ketamine increased with the amount of preoperatively administered
350 opioids.[30, 31] Recently Nielsen et al. (2019) showed that perioperative intravenous S-ketamine
351 reduced analgesic use and pain and improved labor market attachment of opioid-dependent
352 patients one year after spine surgery.[32] Another recent study further confirmed that postoperative
353 low-dose ketamine infusion reduced hydromorphone requirements for the first 24 h after spinal
354 fusion surgery in opioid-tolerant patients, but not in opioid-naïve patients.[33] However, it is
355 recognized that previous opioid use alters pain processing, and these patients typically require
356 higher opioid doses postoperatively. Thus, results of these studies cannot be directly applied to
357 all patients.

358 Although the effect of adjunct ketamine in the opioid-tolerant patient population after lumbar
359 fusion surgery is quite well established, the effect in the opioid-naïve population is less clear.
360 Additionally, the optimal dose of adjunct ketamine in an opioid IV-PCA is unknown. Data
361 indicating low incidence of ketamine-related adverse events (PONV and CNS adverse events)
362 has been consistent in previous studies.[11,12,33] Likewise, our study showed that adjunct S-
363 ketamine in oxycodone IV-PCA was well tolerated. There are several reports of ketamine's
364 beneficial effect on analgesia, opioid-sparing, and PONV in the postoperative period, without

365 increasing the risk for hallucinations. However, the opioid:ketamine ratio in IV-PCA in previous
366 studies was heterogeneous, ranging from 1:0.5 to 1:2.5, and these studies were also
367 heterogeneous in regard to the opioid used, anesthesia methodology, type of surgery, patient
368 population, and use of racemic- or S-ketamine.[34,35]

369 Our study has limitations. Our study was designed to detect a difference in 24 h cumulative
370 oxycodone consumption, which was the primary outcome. The beneficial effect of adjunct S-
371 ketamine in an oxycodone IV-PCA in reducing the 24 h oxycodone consumption did not
372 correlate with a reduction in opioid-related side effects, but this could be secondary to a lack of
373 power. On the other hand, the strengths of our study include that the patient population was
374 homogenous across study groups, consisting of adult men and women who underwent
375 posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation.

376 Postoperative analgesic consumption as a surrogate measure for pain has been criticized on the
377 basis of reports that it is skewed, where a minority of patients consume more than half of the
378 postoperative analgesic. A recent study encouraged reporting categorized parameters as more
379 clinically intuitive.[36] As discussed before, dichotomizing continuous measures leads to several
380 problems.[37] Previously, analgesic consumption has been analyzed with point estimates or
381 determining area under the curve, but both of these methods introduce considerable bias.
382 Statisticians recommend using a model-based approaches, which has been used here. Therefore,
383 both mean (SD) and median (IQR) have been reported. From a clinical perspective, it may be
384 unrealistic to achieve a totally pain-free state after major surgical trauma following surgery such
385 as instrumented lumbar spinal fusion. We think that IV-PCA enables the patient to titrate the
386 opioid to reach a certain individual, tolerable pain intensity level. Therefore, we consider that
387 changes in cumulative opioid consumption could serve as an acceptable surrogate for changes in

postoperative pain. However, we also evaluated the outcome by using risk ratios for pain intensity NRS >3 as a surrogate for perioperative pain experience, and adjunct S-ketamine seemed to decrease the likelihood of pain exceeding NRS >3.

Our study adds new data considering the optimal dose of adjunct S-ketamine to an oxycodone IV-PCA after lumbar spinal fusion surgery. Because the oxycodone:S-ketamine ratio of 1:0.75 was not associated with increased adverse events, we suggest that future studies aimed at solving the optimal opioid:S-ketamine ratio evaluate that dose and higher, possibly with pharmacokinetic testing to characterize the dose-concentration-effect relationship.

In conclusion, IV-PCA containing adjunct S-ketamine with oxycodone at a ratio of 1:0.75 after major lumbar spinal fusion surgery is effective in decreasing the total oxycodone consumption at 24 h after surgery. This oxycodone:S-ketamine ratio is also well tolerated. As previous studies have mainly focused on intraoperative administration, even showing no analgesic effect of intraoperative S-ketamine in opioid-naïve patients[38], this finding adds new data to the feasibility of adjunct S-ketamine with oxycodone for postoperative pain management after major lumbar spinal fusion surgery.

Funding: This work was supported by a governmental research grant from the Hospital District of South-West Finland, Finland (#13821) (TIS).

Conflicts of interest: None.

Clinical Trial Number: clinicaltrials.gov #NCT02994173; Date of registration: September 11, 2017.

Abbreviated title: PCA with S-ketamine reduces postoperative opioid need

Author contributions:

Elina CV Brinck: This author helped in study planning, study conduct, data analysis, and writing and revision of the manuscript.

Taru Virtanen and Venla Soini: These authors helped in study conduct, data analysis, and writing and revision of the manuscript.

Sanna Mäkelä: This author helped in study conduct and revision of the manuscript.

Ville-Veikko Hynninen, Jukka Mulo, Urmas Savolainen, Juho Rantakokko, Kreu Maisniemi, and Antti Liukas: These authors helped in study conduct

Klaus T. Olkkola, Vesa K Kontinen and Pekka Tarkkila: These authors helped in study design and planning, study conduct, and revision of the manuscript.

Marko Peltoniemi This author helped in study design and planning, data analysis, and writing and revision of the manuscript.

Teijo I. Saari: This author was the principal investigator. He helped in study design and planning, data analysis, statistical inference, and writing and revision of the manuscript.

All authors accepted the final manuscript.

Keywords: postoperative; analgesia; PCA clinical advantages; opioid; ketamine

Acknowledgments

Eliisa Löyttyniemi, MSc, Institute of Biomedicine, University of Turku gave invaluable statistical help. The nursing staff of K- and T-operating units, TYKS ORTO, and neurosurgical

429 wards at Turku University Hospital (Turku, Finland) and the staff of surgical ward 2 and the
430 anesthesia nurses of the Department of Orthopaedics and Trauma Surgery at Töölö Hospital
431 (Helsinki, Finland) are acknowledged for their support conducting the study. Sini Alanko, RN;
432 Toni Broman, RN; Virva Kuusisto, RN; and Jaana Virtanen, RN are thanked for their help at the
433 preoperative clinic. Tuula Eklund, RN; Ulla Simola, RN; and Saku Koskinen, RN are
434 acknowledged for their generous help with the patient data system. Local hospital pharmacies in
435 Turku and Helsinki University Hospitals are acknowledged, and ward pharmacists Anne
436 Honkanen, Kira Honkanen, Elina Luoto, Leea Rissanen, Mari Saalasti and Reija Silvennoinen
437 are thanked for fruitful collaboration.

438

439 **References**

440 1. Gerbershagen HJ, Aduckathil S, van Wijck AJM, Peelen LM, Kalkman CJ, Meissner W.
441 Pain intensity on the first day after surgery: a prospective cohort study comparing 179
442 surgical procedures. *Anesthesiology*. 2013;118:934–944.
443 2. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention.
444 *Lancet.* 2006;367:1618–1625.
445 3. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a
446 national survey suggest postoperative pain continues to be undermanaged. *Anesth Analg.*
447 2003;97:534–540.
448 4. Kurd MF, Kreitz T, Schroeder G, Vaccaro AR. The role of multimodal analgesia in spine
449 surgery. *J Am Acad Orthop Surg.* 2017;25:260–268.
450 5. Cozowicz C, Bekeris J, Poeran J, Zubizarreta N, Schwenk E, Girardi F, et al. Multimodal
451 pain management and postoperative outcomes in lumbar spine fusion surgery: a
452 population-based cohort study. *Spine* (Phila Pa 1976). 2020;45:580–589.
453 6. McNicol E, Ferguson MC, Hudcova J. Patient-controlled analgesia versus non-patient
454 controlled analgesia for postoperative pain. *Cochrane Database Syst Rev.*
455 2015;6:CD003348.
456 7. Dinges HC, Otto S, Stay DK, Bäumlein S, Waldmann S, Kranke P, et al. Side effect rates
457 of opioids in equianalgesic doses via intravenous patient-controlled analgesia: a systematic
458 review and network meta-analysis. *Anesth Analg.* 2019;129:1153–1162.
459 8. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical
460 pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin*
461 *Pharmacokinet.* 2016;55:1059–1077.

462 9. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of
463 pain. *Cell.* 2009; 139:267–284.
464 10. Hirota K, Lambert DG. Ketamine: new uses for an old drug? *Br J Anaesth.* 2011;107:123–
465 126.
466 11. Woolf CJ. Pain amplification—a perspective on the how, why, when, and where of central
467 sensitization. *J Appl Biobehav Res.* 2018;23:e12124.
468 12. Brinck EC, Tiippana E, Heesen M, Bell RF, Straube S, Moore RA, et al. Perioperative
469 intravenous ketamine for acute postoperative pain in adults. *Cochrane Database Syst Rev.*
470 2018;12:CD012033.
471 13. Assouline B, Tramèr MR, Kreienbühl L, Elia N. Benefit and harm of adding ketamine to
472 an opioid in a patient-controlled analgesia device for the control of postoperative pain:
473 systematic review and meta-analyses of randomized controlled trials with trial sequential
474 analyses. *Pain.* 2016;157:2854–2864.
475 14. Sveticic G, Gentilini A, Eichenberger U, Luginbühl M, Curatolo M. Combinations of
476 morphine with ketamine for patient-controlled analgesia: a new optimization method.
477 *Anesthesiology.* 2003;98:1195–11205.
478 15. Sveticic G, Eichenberger U, Curatolo M. Safety of mixture of morphine with ketamine for
479 postoperative patient-controlled analgesia: an audit with 1026 patients. *Acta Anaesthiol*
480 *Scand.* 2005;49:870–875.
481 16. Sveticic G, Farzanegan F, Zmoos P, Zmoos S, Eichenberger U, Curatolo M. Is the
482 combination of morphine with ketamine better than morphine alone for postoperative
483 intravenous patient-controlled analgesia? *Anesth Analg.* 2008;106:287–293, table of
484 contents.

485 17. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, et al. The
486 influence of age on propofol pharmacodynamics. *Anesthesiology.* 1999; 90:1502–1516.
487 18. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Billard V, et al. Influence of
488 age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model
489 development. *Anesthesiology.* 1997; 86:10–23.
490 19. Lin T-F, Yeh Y-C, Lin F-S, Wang Y-P, Sun W-Z, Fan S-F. Effect of combining
491 dexmedetomidine and morphine for intravenous patient-controlled analgesia. *Br J Anaesth.*
492 2009;102:117–122.
493 20. Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of
494 some recommended measures of effect size. *Trends Sport Sci.* 2014;1:19–25.
495 21. RStudio Team. RStudio: Integrated Development Environment for R. 2020. Available at:
496 http://www.rstudio.com/. Accessed: 13 March, 2020.
497 22. R Core Team. R: A Language and Environment for Statistical Computing. 2019. Available
498 at: http://www.r-project.org/. Accessed: 13 March 2020.
499 23. Austin PC. Using the standardized difference to compare the prevalence of a binary
500 variable between two groups in observational research. *Commun Stat Simul Comput*.
501 2009;38:1228–1234.
502 24. Pendi A, Field R, Farhan S-D, Eichler M, Bederman SS. Perioperative ketamine for
503 analgesia in spine surgery: a meta-analysis of randomized controlled trials. *Spine (Phila Pa*
504 *1976).* 2018; 43:E299–E307.
505 25. Pacreu S, Fernández Candil J, Moltó L, Carazo J, Fernández Galinski S. The perioperative
506 combination of methadone and ketamine reduces post-operative opioid usage compared
507 with methadone alone. *Acta Anaesthiol Scand.* 2012;56:1250–1256.

508 26. Yeom JH, Chon M-S, Jeon WJ, Shim J-H. Perioperative ketamine with the ambulatory
509 elastometric infusion pump as an adjuvant to manage acute postoperative pain after spinal
510 fusion in adults: a prospective randomized trial. *Korean J Anesthesiol.* 2012;63:54–58.
511 27. Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and
512 morphine with ketamine for postoperative analgesia. *Can J Anaesth.* 1996;43:212–215.
513 28. Nitta R, Goyagi T, Nishikawa T. Combination of oral clonidine and intravenous low-dose
514 ketamine reduces the consumption of postoperative patient-controlled analgesia morphine
515 after spine surgery. *Acta Anaesthesiol Taiwan.* 2013;51:14–17.
516 29. Song JW, Shim JK, Song Y, Yang SY, Park SJ, Kwak YL. Effect of ketamine as an
517 adjunct to intravenous patient-controlled analgesia, in patients at high risk of postoperative
518 nausea and vomiting undergoing lumbar spinal surgery. *Br J Anaesth.* 2013;111:630–635.
519 30. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK. et al.
520 Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent
521 patients with chronic back pain undergoing back surgery. *Anesthesiology.* 2010;113:639–
522 646.
523 31. Nielsen RV, Fomsgaard JS, Siegel H, Martuseviicius R,Nikolajsen L, Dahl JB, al.
524 Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal
525 fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded
526 trial. *Pain.* 2017;158:463–470.
527 32. Nielsen RV, Fomsgaard JS, Nikolajsen L, Dahl JB, Mathiesen O. Intraoperative S-
528 ketamine for the reduction of opioid consumption and pain one year after spine surgery: a
529 randomized clinical trial of opioid-dependent patients. *Eur J Pain.* 2019;23:455–460.

530 33. Boenigk K, Echevarria GC, Nisimov E, Bergen Granell AE von, Cuff GE, Wang J,
531 Atchabahian A. Low-dose ketamine infusion reduces postoperative hydromorphone
532 requirements in opioid-tolerant patients following spinal fusion: a randomised controlled
533 trial. *Eur J Anaesthesiol.* 2019;36:8–15.
534 34. Wang L, Johnston B, Kaushal A, Cheng D, Zhu F, Martin J. Ketamine added to morphine
535 or hydromorphone patient-controlled analgesia for acute postoperative pain in adults: a
536 systematic review and meta-analysis of randomized trials. *Can J Anaesth.* 2016;63:311–
537 325.
538 35. Carstensen M, Møller AM. Adding ketamine to morphine for intravenous patient-
539 controlled analgesia for acute postoperative pain: a qualitative review of randomized trials.
540 *Br J Anaesth.* 2010;104:401–406.
541 36. Moore RA, Mhuircheartaigh RJN, Derry S, McQuay HJ. Mean analgesic consumption is
542 inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative
543 suggestion. *Eur J Anaesthesiol.* 2011;28:427–432.
544 37. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ.*
545 2006;332:1080.
546 38. Brinck ECV, Maisniemi K, Kankare J, Tielinen L, Tarkkila P, Kontinen VK. Analgesic
547 effect of intraoperative intravenous S-ketamine in opioid-naïve patients after major lumbar
548 fusion surgery is temporary and not dose-dependent: a randomized, double-blind, placebo-
549 controlled clinical trial. *Anesth Analg.* 2021;132:69–79.

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	4-5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	-
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7,9
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9-10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	-

Sample size	7a	How sample size was determined	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	-
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	7
	11b	If relevant, description of the similarity of interventions	-
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10-11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	-
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12
	13b	For each group, losses and exclusions after randomisation, together with reasons	12
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	12
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	12, table 1

Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	12
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	15, table 2
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	20-21
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	-
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	21
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	24
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	25
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	25
Other information			
Registration	23	Registration number and name of trial registry	6
Protocol	24	Where the full trial protocol can be accessed, if available	1,6
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	8

553